Beyond traditional angiogenesis, EphA2 plays a pivotal role in VM, particularly in aggressive tumours such as glioma, ovarian, gastric, and prostate cancers, where it facilitates tumour cell plasticity, enabling cancer cells to adopt endothelial-like phenotypes and form perivascular vessel-like networks [40,64,69,70,71]. This evidence concerns the gene EPHA2 and prostate carcinoma.